Latest Content

From an approval for a disease affecting 900 people worldwide to a new drug class in multiple myeloma and a $322 million biosimilar collaboration — this week's deals and approvals reveal a lot about how pharmaceutical strategy is evolving.

Amplitude Therapeutics enters a collaboration with Eli Lilly to develop trans-amplifying RNA vaccines, while Chai Discovery partners with Bristol Myers Squibb to deploy its AI molecular folding and design models across BMS's antibody discovery portfolio.

K2 Therapeutics CEO Ying Huang discusses why government investment and US-trained returnees have made China's biotech innovation surge irreversible.

Norstella’s VP of thought leadership discusses why pharma spent more on R&D, got fewer drugs, and is heading toward a $500 billion patent cliff unprepared.

A partnership roundup covers deals from IntraGel Therapeutics/UroGen Pharma and Lupin/Tenpoint Therapeutics, FDA approves Regeneron's Pasatru for fibrodysplasia ossificans progressiva, and RELEX's Rohit Tripathi discusses reshoring pharma manufacturing.

UroGen Pharma has invested in IntraGel Therapeutics and secured an exclusive option to license Tumocure, and Lupin's subsidiary has licensed European commercialization rights to Tenpoint's Yuvezzi.

FDA has approved Regeneron's Pasatru ,the first treatment for fibrodysplasia ossificans progressiva in adults.

Rohit Tripathi, VP of Industry Strategy at RELEX, talks with Pharmaceutical Executive about the impact new phased tariffs will have on reshoring pharma manufacturing.

In pharma's AI transformation, the technology was never the hard part — fixing the operating model that has to act on what AI surfaces is.

How drug pricing, tariffs, and manufacturing decisions are becoming connected.

President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for FDA commissioner.

Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the leaders from the rest.

Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy is producing structural change.